Sulfonylureas and basal insulin linked to elevated cardiovascular risk
Sulfonylureas and basal insulin confer an increased risk of cardiovascular events compared with newer second-line medicines for type 2 diabetes mellitus, research has found.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Insulin